AZ/MSD’s Lynparza wins prostate cancer approval
Lynparza is the only PARP inhibitor to improve overall survival versus enzalutamide or abiraterone in prostate cancer patients with BRCA1/2 or ATM mutations
Read More
Tag: mCRPC
AZ, MSD’s Lynparza/abiraterone combo hits prostate cancer goals
AstraZeneca and MSD have presented data at ASCO showing improvement in radiologic progression-free survival in prostate cancer patients taking a combination of Lynparza and abiraterone.
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
